4.61
price down icon4.16%   -0.20
after-market Dopo l'orario di chiusura: 4.61
loading
Precedente Chiudi:
$4.81
Aprire:
$4.8
Volume 24 ore:
357.55K
Relative Volume:
0.80
Capitalizzazione di mercato:
$279.07M
Reddito:
-
Utile/perdita netta:
$-69.31M
Rapporto P/E:
-3.6299
EPS:
-1.27
Flusso di cassa netto:
$-62.80M
1 W Prestazione:
-6.11%
1M Prestazione:
-2.33%
6M Prestazione:
+5.98%
1 anno Prestazione:
+271.77%
Intervallo 1D:
Value
$4.61
$4.87
Intervallo di 1 settimana:
Value
$4.61
$5.28
Portata 52W:
Value
$1.13
$6.1856

Rezolute Inc Stock (RZLT) Company Profile

Name
Nome
Rezolute Inc
Name
Telefono
650-206-4507
Name
Indirizzo
275 SHORELINE DRIVE, SUITE 500, REDWOOD CITY
Name
Dipendente
59
Name
Cinguettio
Name
Prossima data di guadagno
2025-02-11
Name
Ultimi documenti SEC
Name
RZLT's Discussions on Twitter

Confronta RZLT con altri titoli

Azioni Prezzo Cap. di mercato Reddito Reddito netto Flusso di cassa EPS
Biotechnology icon
RZLT
Rezolute Inc
4.61 279.07M 0 -69.31M -62.80M -1.27
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
459.00 117.92B 11.02B -535.60M -978.00M -2.20
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
673.60 73.64B 14.20B 4.41B 3.54B 38.28
Biotechnology icon
ARGX
Argen X Se Adr
639.41 38.85B 1.86B -40.29M -1.28B -0.85
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
256.45 33.20B 2.09B -332.26M 16.06M -2.62
Biotechnology icon
BNTX
Biontech Se Adr
119.83 28.73B 3.30B -501.07M 1.03B -2.1146

Rezolute Inc Stock (RZLT) Upgrades & Downgrades

Data Azione Analista Modifica della valutazione
2024-11-05 Iniziato Wedbush Outperform
2024-08-27 Iniziato Guggenheim Buy
2024-07-17 Iniziato BTIG Research Buy
2024-06-04 Iniziato Craig Hallum Buy
2024-04-09 Iniziato Maxim Group Buy
2022-08-02 Ripresa Canaccord Genuity Buy
2022-06-15 Iniziato Cantor Fitzgerald Overweight
2021-09-08 Iniziato ROTH Capital Buy
2021-05-27 Iniziato Oppenheimer Outperform
2021-05-25 Iniziato H.C. Wainwright Buy
Mostra tutto

Rezolute Inc Borsa (RZLT) Ultime notizie

pulisher
Feb 14, 2025

Rezolute’s Strategic Advances in Rare Disease Therapies - TipRanks

Feb 14, 2025
pulisher
Feb 14, 2025

Rezolute (NASDAQ:RZLT) Given New $9.00 Price Target at JMP Securities - MarketBeat

Feb 14, 2025
pulisher
Feb 13, 2025

Rezolute's (RZLT) "Buy" Rating Reaffirmed at HC Wainwright - MarketBeat

Feb 13, 2025
pulisher
Feb 13, 2025

JMP Securities lifts Rezolute stock target to $9, maintains rating - MSN

Feb 13, 2025
pulisher
Feb 13, 2025

JMP Securities lifts Rezolute stock target to $9, maintains rating By Investing.com - Investing.com South Africa

Feb 13, 2025
pulisher
Feb 13, 2025

Rezolute (NASDAQ:RZLT) Issues Quarterly Earnings Results - MarketBeat

Feb 13, 2025
pulisher
Feb 12, 2025

Rezolute Inc reports results for the quarter ended December 31Earnings Summary - TradingView

Feb 12, 2025
pulisher
Feb 12, 2025

Rezolute Inc. (RZLT) reports earnings - Quartz

Feb 12, 2025
pulisher
Feb 12, 2025

Rezolute, Inc. SEC 10-Q Report - TradingView

Feb 12, 2025
pulisher
Feb 12, 2025

Rezolute's Hyperinsulinism Drug Hits Major FDA Milestone as Q2 Shows $105M War Chest - StockTitan

Feb 12, 2025
pulisher
Feb 12, 2025

Analysts Set Rezolute, Inc. (NASDAQ:RZLT) PT at $24.13 - Defense World

Feb 12, 2025
pulisher
Feb 12, 2025

H.C. Wainwright reiterates Buy on Rezolute shares, $14 target - MSN

Feb 12, 2025
pulisher
Feb 11, 2025

Rezolute (NASDAQ:RZLT) Receives Buy Rating from Guggenheim - Defense World

Feb 11, 2025
pulisher
Feb 10, 2025

Rezolute (NASDAQ:RZLT) Receives "Buy" Rating from Guggenheim - MarketBeat

Feb 10, 2025
pulisher
Feb 09, 2025

Rezolute, Inc. (NASDAQ:RZLT) Receives Consensus Recommendation of "Buy" from Analysts - MarketBeat

Feb 09, 2025
pulisher
Feb 09, 2025

Rezolute (NASDAQ:RZLT) Raised to Strong-Buy at Craig Hallum - MarketBeat

Feb 09, 2025
pulisher
Feb 08, 2025

Rezolute (NASDAQ:RZLT) Given Buy Rating at HC Wainwright - MarketBeat

Feb 08, 2025
pulisher
Feb 08, 2025

Rezolute’s (RZLT) Buy Rating Reiterated at HC Wainwright - Defense World

Feb 08, 2025
pulisher
Feb 07, 2025

Rezolute Inc (RZLT) Shares Decline Despite Market Challenges - The News Heater

Feb 07, 2025
pulisher
Feb 07, 2025

Analytical Overview: Rezolute Inc (RZLT)’s Ratios Tell a Financial Story - The Dwinnex

Feb 07, 2025
pulisher
Feb 07, 2025

Rezolute (RZLT) to Announce Earnings on Tuesday - MarketBeat

Feb 07, 2025
pulisher
Feb 07, 2025

Rezolute (NASDAQ:RZLT) Upgraded at Craig Hallum - Defense World

Feb 07, 2025
pulisher
Feb 06, 2025

RZLT Shares Rise 30.8% in 6 Months: What's Driving the Rally? - MSN

Feb 06, 2025
pulisher
Feb 06, 2025

What is the investor’s view on Rezolute Inc (RZLT)? - US Post News

Feb 06, 2025
pulisher
Feb 05, 2025

Rezolute's ersodetug advances in pediatric study - MSN

Feb 05, 2025
pulisher
Feb 05, 2025

The Attractiveness of Investing In Rezolute Inc (RZLT) is Growing - Knox Daily

Feb 05, 2025
pulisher
Feb 05, 2025

H.C. Wainwright reiterates Buy on Rezolute shares, $14 target By Investing.com - Investing.com South Africa

Feb 05, 2025
pulisher
Feb 05, 2025

JPMorgan Chase & Co. Purchases New Holdings in Rezolute, Inc. (NASDAQ:RZLT) - Defense World

Feb 05, 2025
pulisher
Feb 04, 2025

Rezolute Advances SunRIZE Study for Hypoglycemia Treatment - TipRanks

Feb 04, 2025
pulisher
Feb 04, 2025

Rezolute Provides Update on its Phase 3 sunRIZE Study of Ersodetug for the Treatment of Hypoglycemia Due to Congenital Hyperinsulinism - Marketscreener.com

Feb 04, 2025
pulisher
Feb 04, 2025

Rezolute, Inc. Reports Positive DMC Review of sunRIZE Study for Ersodetug in Infants with Hyperinsulinism - Nasdaq

Feb 04, 2025
pulisher
Feb 04, 2025

Rezolute Provides Update on its Phase 3 sunRIZE Study of Ersodetug for the Treatment of Hypoglycemia Due to - EIN News

Feb 04, 2025
pulisher
Feb 03, 2025

Rezolute to Participate in the Guggenheim SMID Cap Biotech Conference -February 03, 2025 at 09:06 am EST - Marketscreener.com

Feb 03, 2025
pulisher
Feb 02, 2025

(RZLT) Trading Report - Stock Traders Daily

Feb 02, 2025
pulisher
Jan 31, 2025

Rezolute to Participate in the Guggenheim SMID Cap Biotech Conference - The Manila Times

Jan 31, 2025
pulisher
Jan 31, 2025

Rezolute to Participate in the Guggenheim SMID Cap Biotech Conference -January 31, 2025 at 08:01 am EST - Marketscreener.com

Jan 31, 2025
pulisher
Jan 31, 2025

Rare Disease Pioneer Rezolute Takes Center Stage at Elite Guggenheim Biotech Conference - StockTitan

Jan 31, 2025
pulisher
Jan 27, 2025

Rezolute receives breakthrough therapy designation for treatment of hypoglycemia - MSN

Jan 27, 2025
pulisher
Jan 23, 2025

Cantor Fitzgerald Predicts Rezolute FY2025 Earnings - MarketBeat

Jan 23, 2025
pulisher
Jan 18, 2025

Rezolute, Inc. (NASDAQ:RZLT) Receives $24.13 Average Target Price from Analysts - Defense World

Jan 18, 2025
pulisher
Jan 15, 2025

Brokerages Set Rezolute, Inc. (NASDAQ:RZLT) Price Target at $24.13 - MarketBeat

Jan 15, 2025
pulisher
Jan 14, 2025

Rezolute shares Phase 2 clinical study update By Investing.com - Investing.com South Africa

Jan 14, 2025
pulisher
Jan 14, 2025

Rezolute shares Phase 2 clinical study update - Investing.com

Jan 14, 2025
pulisher
Jan 14, 2025

Rezolute Highlights Promising Phase 2 Ersodetug Results - TipRanks

Jan 14, 2025
pulisher
Jan 11, 2025

(RZLT) On The My Stocks Page - Stock Traders Daily

Jan 11, 2025
pulisher
Jan 08, 2025

Top 5 Small-cap Biotech Stocks (Updated January 2025) - Investing News Network

Jan 08, 2025
pulisher
Jan 08, 2025

Rezolute, Inc. (NASDAQ:RZLT) Shares Acquired by Geode Capital Management LLC - MarketBeat

Jan 08, 2025
pulisher
Jan 07, 2025

Rezolute Gains FDA Breakthrough Designation for Ersodetug - TipRanks

Jan 07, 2025
pulisher
Jan 07, 2025

Here's Why 'Trend' Investors Would Love Betting on Rezolute (RZLT) - Yahoo Finance

Jan 07, 2025
pulisher
Jan 07, 2025

FDA Grants Breakthrough Therapy Status to Rezolute's Ersodetug for Congenital Hyperinsulinism - StockTitan

Jan 07, 2025

Rezolute Inc Azioni (RZLT) Dati Finanziari

Reddito

loading

Reddito netto

loading

Flusso di cassa

loading

EPS

loading
$79.31
price up icon 0.81%
$21.37
price down icon 2.06%
$370.58
price up icon 0.04%
$4.94
price up icon 7.39%
biotechnology ONC
$230.86
price up icon 2.38%
$119.83
price down icon 2.40%
Capitalizzazione:     |  Volume (24 ore):